A recent study reveals that individuals who stop using blockbuster slimming jabs like semaglutide or tirzepatide may regain shed pounds much more quickly than those who end traditional lifestyle programs.
Research printed in a leading medical journal points out that while overweight individuals can lose a large proportion of their body weight while using the jabs, the weight returns at an estimated rate of 0.8 kg per month upon discontinuation.
"People using such medications should be informed of the danger of fast weight regain when the therapy concludes," stated lead investigator Dr. Susan Jebb.
Such speed of regain suggests a return to original mass in about 18 months.
Weighing Therapies
The research, which looked at dozens of studies involving thousands of patients, compared the outcomes of the injectable medications with other pills.
Scientists note that people who shed pounds through diet and exercise typically have a less rapid creep back—around 0.1 kg a month—after stopping.
Understanding the Quick Rebound
Experts suggest the mechanism of the drugs accounts for the amplified rebound.
These medications imitate a body's own chemical called glucagon-like peptide-1, which controls feelings of fullness.
"Long-term administration of GLP-1 levels several times higher than the body's typical production could lead to the system to generate a reduced amount of its endogenous GLP-1, and could lessen responsiveness to its effects," said Dr. Adam Collins, a dietetics specialist.
"Stopping of this medication results in hunger is no longer kept in check, making overeating a significant risk."
A Lifelong Disease?
The NHS suggest the jabs for people with weight-linked health risks, alongside recommended lifestyle changes.
A number of clinicians contend that, due to the significant potential of relapse, the treatment might need to be ongoing.
This opinion is echoed by drug manufacturers, who note that the findings "emphasize the persistent nature of obesity," similar to managing diseases like hypertension.
Patient Accounts
Users who have discontinued the medication describe a powerful resurgence of cravings.
"I experienced a trigger that goes on and you become starving," recalled a patient.
This difficulty is exacerbated if users have not established permanent dietary or behavioural modifications during therapy.
Significant Use
Survey data suggest that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with demand being substantial.
- Adoption is greater among women than men.
- The middle-aged age group shows the highest usage rates.
- Many access the medications through private healthcare rather than public health services.
Finally, researchers stress that while GLP-1 drugs are powerful tools for weight loss, they are not a standalone fix and lasting health benefits likely depends on combined behavioural changes.
